In an alternative dimension, REDUCE-IT would have failed and Vascepa/Amarin wouldn't be getting all of this attention and headlines heading into BETonMACE top-line. In reality, Amarin and the REDUCE-IT clinical investigators are prolificly publishing and presenting at investor and science meetings to promote Vascepa as it heads for the likely approval of its label expansion for cardiovascular indications in a few months. Amarin has quite the line-up of science posters, as well as product promotion, at American Diabetes Association that starts today. Resverlogix has a poster at ADA too, but will likely be outshined by already proven Vascepa. 

AMARIN TO PRESENT FINDINGS REGARDING CHALLENGES OF CURRENT TREATMENT OPTIONS IN REDUCING CARDIOVASCULAR RISKS FOR DIABETES PATIENTS, EVEN FOR THOSE WITH CONTROLLED CHOLESTEROL LEVELS, AT ANNUAL AMERICAN DIABETES ASSOCIATION (ADA) MEETING

https://investor.amarincorp.com/news-releases/news-release-details/amarin-present-findings-regarding-challenges-current-treatment

Hopefully now that the share offering is wrapping up, Resverlogix can be more active in promotion again. That April fact sheet is getting rather moldy. I shouldn't be the only one posting about upcoming events. How about an updated Corporate Update on the website to provide something newer than September 2018?

BDAZ